<![CDATA[Epcoritamab/R2 Earns European Approval for R/R Follicular Lymphoma]]>
RegulatoryapprovedEpcoritamab/R2Positive
AI Analysis
Summary
The European Commission approved epcoritamab/R2 for adult patients with relapsed/refractory follicular lymphoma based on positive Phase 3 EPCORE FL-1 data.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
European Commission approval for adult patients with relapsed/refractory follicular lymphoma
Importance:8/10
Sentiment:
0.90
European approvalFollicular lymphomaLymphomaPhase 3Regulatory approval
Related Companies
Read the original article
Published by Cancer Network on July 7, 2026 6:00 PM